Aliskiren-based dual- and triple-combination therapies in high-risk US minority patients with Stage 2 hypertension

Journal of the American Society of Hypertension

Volumn 6, Issue 3, 2012, Pages 219-227

  Ferdinand, Keith C ^a,b   Weitzman, Richard ^c   Purkayastha, Das ^c   Sridharan, Kanaka ^c   Jaimes, Edgar A ^d  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Association of Black Cardiologists Inc   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Blacks; cardiometabolic syndrome; diabetes; obesity

Indexed keywords

ALISKIREN PLUS AMLODIPINE; ALISKIREN PLUS AMLODIPINE PLUS HYDROCHLOROTHIAZIDE; AMLODIPINE; POTASSIUM;

ADULT; ARTICLE; BODY WEIGHT; CARDIOMETABOLIC SYNDROME; CONTROLLED STUDY; DIABETES MELLITUS; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; GLOMERULUS FILTRATION RATE; HIGH RISK PATIENT; HUMAN; HYPERKALEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; MULTICENTER STUDY; OBESITY; OUTCOME ASSESSMENT; PERIPHERAL EDEMA; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; UNITED STATES;

ADULT; AMIDES; AMLODIPINE; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; DIURETICS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; FUMARATES; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; MALE; MIDDLE AGED; MINORITY GROUPS; PREVALENCE; RENIN; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 84859949560     PISSN: 19331711     EISSN: 18787436     Source Type: Journal    
DOI: 10.1016/j.jash.2011.12.002     Document Type: Article

References (20)

1. Egan BM, Zhao Y, Axon RN. US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008. JAMA 2010;303:2043-50.
2. Ferdinand KC, Armani AM. The management of hypertension in African Americans. Crit Pathw Cardiol 2007; 6:67-71. (Pubitemid 46878235)
3. Keenan NL, Rosendorf KA. Prevalence of hypertension and controlled hypertension-United States, 2005-2008. MMWR Surveill Summ 2011;60(Suppl):94-7.
4. Redon J, Cifkova R, Laurent S, Nilsson P, Narkiewicz K, Erdine S, et al. The metabolic syndrome in hypertension: European society of hypertension position statement. J Hypertens 2008;26:1891-900.
5. Cutler JA, Sorlie PD, Wolz M, Thom T, Fields LE, Roccella EJ. Trends in hypertension prevalence, awareness, treatment, and control rates in United States adults between 1988-1994 and 1999-2004. Hypertension 2008;52:818-27.
6. Ogden CL, Carroll MD, Curtin LR, McDowell MA, Tabak CJ, Flegal KM. Prevalence of overweight and obesity in the United States, 1999-2004. JAMA 2006; 295:1549-55.
7. Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation 2008;117:e510-26.
8. Ferdinand KC, Weitzman R, Israel M, Lee J, Purkayastha D, Jaimes EA. Efficacy and safety of aliskiren-based dual and triple combination therapies in US minority patients with stage 2 hypertension. J Am Soc Hypertens 2011;5:102-13.
9. Frohlich ED, Grim C, Labarthe DR, Maxwell MH, Perloff D, Weidman WH. Recommendations for human blood pressure determination by sphygmomanometers: report of a special task force appointed by the Steering Committee, American Heart Association. Hypertension 1988;11:210A-22.
10. Flack JM, Sica DA, Bakris G, Brown AL, Ferdinand KC, Grimm RH Jr, et al. Management of high blood pressure in Blacks: an update of the International Society on Hypertension in Blacks consensus statement. Hypertension 2010;56:780-800.
11. Wright JT Jr, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 2002;288:2421-31. (Pubitemid 35340538)
12. Agodoa LY, Appel L, Bakris GL, Beck G, Bourgoignie J, Briggs JP, et al. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA 2001; 285:2719-28. (Pubitemid 32525368)
13. Wright JT Jr, Rahman M, Scarpa A, Fatholahi M, Griffin V, Jean-Baptiste R, et al. Determinants of salt sensitivity in black and white normotensive and hypertensive women. Hypertension 2003;42:1087-92. (Pubitemid 37549060)
14. Littlejohn TW III, Trenkwalder P, Hollanders G, Zhao Y, Liao W. Long-term safety, tolerability and efficacy of combination therapy with aliskiren and amlodipine in patients with hypertension. Curr Med Res Opin 2009;25:951-9.
15. Drummond W, Munger MA, Rafique EM, Maboudian M, Khan M, Keefe DL. Antihypertensive efficacy of the oral direct renin inhibitor aliskiren as add-on therapy in patients not responding to amlodipine monotherapy. J Clin Hypertens (Greenwich) 2007;9:742-50.
16. Braun-Dullaeus RC, Zhang J, Hristoskova S, Häring DA, Liao W. First-line therapy with aliskiren/amlodipine combination provides robust blood pressure reductions in patients with moderate to severe hypertension. Presented at the 25th Annual Scientific Meeting and Exposition of the American Society of Hypertension. May 1-4, 2010, New York.
17. Brown MJ, McInnes GT, Papst CC, Zhang J, MacDonald TM. Aliskiren and the calcium channel blocker amlodipine combination as an initial treatment strategy for hypertension control (ACCELERATE): a randomised, parallel-group trial. Lancet 2011;377: 312-20.
18. Schmieder RE, Philipp T, Guerediaga J, Gorostidi M, Bush C,Keefe DL. Aliskiren-based therapy lowers blood pressure more effectively than hydrochlorothiazidebased therapy in obese patients with hypertension: subanalysis of a 52-week, randomized, double-blind trial. J Hypertens 2009;27:1493-501.
19. Black HR, Weinberger MH, Purkayastha D, Lee J, Sridharan K, Israel M, et al. Comparative efficacy and safety of combination aliskiren/amlodipine and amlodipine monotherapy in African Americans with stage 2 hypertension. J Clin Hypertens (Greenwich) 2011;13:571-81.
20. Weinberger MH, Izzo JL Jr, Purkayastha D, Weitzman R, Black HR. Comparative efficacy and safety of combination aliskiren/amlodipine and amlodipine monotherapy in African Americans with stage 2 hypertension and obesity or metabolic syndrome. J Am Soc Hypertens 2011;5:489-97.